Montelukast

證據等級: L5

預測適應症: 5 個

Montelukast: From Asthma to Bronchitis

One-Sentence Summary

Montelukast is a leukotriene receptor antagonist (LTRA) with an established, previously proven role in asthma management. The TxGNN model's top-ranked new-indication prediction is Bronchitis, with 23 clinical trials and 20 publications currently identified — though most of this evidence addresses closely related but distinct conditions (bronchiolitis, bronchiolitis obliterans, eosinophilic bronchitis) rather than bronchitis itself, so the evidence is indirect and hypothesis-generating rather than confirmatory.

Quick Overview

Item	Content
Original Indication	Asthma (per known approved use — noted in the rank-3 candidate's rationale as montelukast's established indication; not available from NZ license data since the drug is unmarketed there)
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.95%
Evidence Level	L2
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, montelukast is a selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist that blocks LTD4-mediated bronchoconstriction, mucus hypersecretion, vascular permeability, and eosinophil recruitment — its proven mechanism in asthma, an indication directly confirmed by this evidence pack's own asthma candidate (L1 evidence, Phase 3 RCTs, "known/approved indication, not a repurposing hypothesis").

Asthma and bronchitis both involve airway inflammation and bronchial hyperresponsiveness, so there is a plausible mechanistic bridge. However, the bulk of the clinical evidence gathered under the "bronchitis" label actually concerns adjacent-but-distinct diagnoses: viral bronchiolitis in infants, bronchiolitis obliterans syndrome (BOS) after transplantation, and non-asthmatic eosinophilic bronchitis (NAEB) — each with different pathophysiology (transplant rejection, RSV-driven inflammation, isolated eosinophilic infiltration) than typical infectious/chronic bronchitis. Only one trial (NCT04613180) and a handful of literature reports directly target recurrent obstructive bronchitis or NAEB with montelukast, and results are mixed (e.g., a 2018 systematic review found non-significant benefit in leukotriene antagonist use for eosinophilic airway disease overall). This makes the mechanistic rationale plausible but the direct clinical support still preliminary.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04613180	Phase 4	Unknown	100	Evaluated montelukast for treatment/prevention of recurrent obstructive bronchitis in children 1–7 years; the only trial directly targeting this exact indication, but status/results unreported
NCT00076973	Phase 3	Completed	1125	Two-dose montelukast vs placebo for respiratory symptoms of RSV-induced bronchiolitis in children 3–24 months
NCT02479074	Phase 4	Completed	49	Compared montelukast vs prednisolone on 24-hr cough counts in chronic cough patients with elevated feNO
NCT03369119	Phase 4	Completed	100	Assessed additive benefit of oral montelukast added to standard care in preschoolers hospitalized for acute asthma/wheeze
NCT01370187	N/A	Completed	146	Montelukast for acute bronchiolitis and post-bronchiolitis viral-induced wheezing in infants 3–12 months
NCT05293132	Phase 2/3	Completed	90	Montelukast vs coenzyme Q10 for clinical outcomes in sepsis patients — anti-inflammatory/antioxidant rationale, not bronchitis-specific
NCT01432080	Phase 2	Terminated	12	Immunosuppression escalation to prevent transplant-associated lung disease after viral respiratory infection post-HSCT
NCT01211509	Phase 4	Completed	30	RCT of montelukast for bronchiolitis obliterans syndrome (BOS) after lung transplantation
NCT00863317	N/A	Completed	141	Double-blind RCT of daily montelukast for viral bronchiolitis, primary outcome duration of acute illness
NCT00656058	Phase 2	Completed	25	Multi-institutional trial of montelukast for bronchiolitis obliterans following stem cell transplantation

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25563311	2015	RCT	Chinese Medical Journal	Add-on montelukast to budesonide improved airway eosinophilia, cough, and quality of life in non-asthmatic eosinophilic bronchitis (NAEB)
20976161	2010	RCT	PLoS One	Montelukast and fish oil, alone/combined, reduced airway inflammation and exercise-induced bronchoconstriction
38485149	2024	Clinical Practice Guideline	European Respiratory Journal	ERS/EBMT guideline on treatment of pulmonary chronic graft-versus-host disease, including montelukast's role in BOS
38504551	2024	Review	Therapeutic Advances in Respiratory Disease	Reviews therapeutic potential and mechanisms of montelukast in bronchiolitis obliterans syndrome after transplantation
30038355	2019	Review	Bone Marrow Transplantation	Diagnostic/therapeutic challenges in bronchiolitis obliterans syndrome after hematopoietic cell transplantation
21486501	2011	Review	BMJ Clinical Evidence	General overview of bronchiolitis epidemiology and management in infants
24345788	2014	Review (mechanism)	Current Opinion in Allergy and Clinical Immunology	Reviews mechanisms of chronic cough, relevant to leukotriene-mediated airway hypersensitivity
28545478	2017	Animal/Mechanistic	Journal of Cardiothoracic Surgery	Rat model implicating LTB4 and montelukast in transplantation-related bronchiolitis obliterans
35114411	2022	Phase II Trial	Transplantation and Cellular Therapy	Prospective Phase II trial of montelukast for BOS after hematopoietic cell transplant; investigated pathogenesis
24118637	2014	Systematic Review	Pediatric Allergy and Immunology	Systematic review of montelukast's efficacy for preventing post-bronchiolitis wheezing

New Zealand Market Information

Montelukast is currently not marketed in New Zealand (market_status: 未上市), and no product authorizations are on record (total_licenses: 0). No license or product data is available to summarize.

Safety Considerations

Please refer to the package insert for safety information (no key warnings, contraindications, or drug interaction data are available for this drug — TFDA package insert warnings/contraindications remain a Blocking data gap, per this pack's data_gaps list).

Note from literature review: although not part of the formal safety data field, several publications surfaced during the literature search (e.g. PMID 37758273, 36948487, 35608857, 39836401) reference a US FDA boxed warning (2020) on neuropsychiatric adverse events associated with montelukast. This signal should be incorporated into any formal safety evaluation before proceeding.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic rationale (CysLT1 antagonism reducing airway inflammation) is reasonable, and one trial and several publications support benefit specifically in non-asthmatic eosinophilic bronchitis, but most of the assembled evidence actually addresses distinct conditions (viral bronchiolitis, post-transplant bronchiolitis obliterans) rather than bronchitis itself, and TFDA safety data is a Blocking gap.

To proceed, the following is needed:

TFDA/manufacturer package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism-of-action documentation (DG002)
A trial or evidence set specifically targeting bronchitis (not bronchiolitis/BOS/NAEB as proxies) to establish direct efficacy
Formal safety assessment incorporating the FDA neuropsychiatric boxed warning identified in the literature
New Zealand regulatory pathway assessment, since the drug is not currently marketed there
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.